This is the authors' abstract. We don't add key points for this paper.
SUMMARY The TALAPRO-2 trial[1] was a randomized, placebo, controlled, multicentric, multinational, double-blind, phase 3 trial of talazoparib plus enzalutamide (Talazo + Enza) versus placebo plus enzalutamide as first-line therapy for >18 years (>20 years in Japan) men of prostate cancer. Patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) and receiving continued androgen deprivation therapy were enrolled in this trial, which was conducted in 223 hospitals among different centers in 26 countries across the globe. Patients were prospectively evaluated for HRR gene mutation in prostate cancer tissue and randomly assigned 1:1 ratio in two groups. The intervention group received talazoparib 0.5 mg with enzalutamide 160 mg once daily orally, while the comparator group received enzalutamide 160 mg with placebo. Randomization was stratified by HRR gene status absent versus present or unknown and previous treatment like docetaxel/abiraterone or both before developing castration-resistant prostate cancer. Patients and investigators were blinded for talazoparib or placebo, but enzalutamide was open level. The primary endpoint of the study was to evaluate radiographic progression-free survival (RPFS) and adverse effect of therapy in intention to treat population in those who received at least one dose. Total 805 patients were enrolled in the study and 402 patients assigned in talazoparib group and 403 in placebo group randomly. The median follow-up in both the groups for RPFS was comparable, 24.9 months for talazoparib and 24.6 months for placebo group. On analysis, the median RPFS was not reached (95% confidence interval [CI]: 27.5 months) for Talazo + Enza and 21·9 months (16·6–25·1) for placebo plus enzalutamide (hazard ratio [HR]: 0·63; 95% CI: 0·51–0·78; P < 0·0001). The most common adverse drug events (ADEs) were anemia, neutropenia, and fatigue. The grade 3–4 ADE was anemia seen in 185 patients, which is 46% of total, which was improved after dose reduction and only 8% of patients discontinued talazoparib. No deaths reported in this group, while two patients (<1%) died in the placebo group. This randomized controlled trial (RCT) conclude that Talazo + Enza combination gives promising result with a significant improvement in RPFS in comparison to enzalutamide monotherapy as first-line treatment in mCRPC. This combination lowered the risk of radiographic progression or death by 37% and caused minimal side effects. COMMENTS TALAPRO-2 trial[1] was well structured and enrolled only mCRPC patients with no symptoms or minimal symptoms. This trial showed that combination of PARP (poly ADP_ribose polymerases) inhibitor with enzalutamide delivers better outcome than either of drugs. There are two more PARP inhibitors already available for mCRPC treatment with germline mutation. Olaparib and rucaparib are earlier generation drugs in this category. Robust data from the PROFound trial[2] and TRITON trial[3] has already shown favorable outcomes with PARP inhibitor monotherapy in mCRPC in patients who progressed on enzalutamide and abiraterone. Both these studies were randomized, controlled, phase 3 study which enrolled mCRPC patients in 2:1 ratio with BRCA-1, BRCA-2, or ATM mutations. Progression-free survival was significantly longer for olaparib and rucaparib, median 7.4 months and 11.2 months respectively, than control who received either enzalutamide or abiraterone acetate. The major side effects of these drugs were anemia, nausea, and fatigue. These were slightly lower for monotherapy with these drugs than in the TALAPRO-2 trial where combination with enzalutamide caused more treatment related adverse effects, especially anemia. A positive role of enzalutamide monotherapy in mCRPC, both after docetaxel and before docetaxel therapy, has already been established in previous studies i.e., theAFFIRM trial[4] and PREVEIL trial[5] respectively. The earlier TALAPRO-1 study, which was an open label, phase 2 trial of Talazoparib as monotherapy, showed durable anticancer activity in mCRPC patients with DDR-HRR gene alteration. Talazoparib (BMN-673) is the third PARP category drug which is orally bioavailable and 100 fold more potent than Olaparib as a PARP inhibitor. It is 74% plasma protein bound and metabolizes <30% so the plasma half-life is around 90 h. It is mainly excreted in urine (69%). The main adverse effects are anemia, neutropenia, thrombocytopenia, headache, nausea, hair loss, and fatigue. Difference of side effect profile between TALAPRO-2 trial and earlier PARP inhibitor trial may be due to combination with enzalutamide in this trial. The strength of this study is that it is an RCT, multicentric, with an adequate sample size. However, the cases of mCRPC included in the study were asymptomatic or mild symptomatic. Whether this combination is effective for moderate-to-severe symptomatic patients is unclear. The follow-up was short (mean 24.9 months). No long-term data are available. Due to ADE, 8% of patients dropped out from the treatment group. However based on the TALAPRO-2[1] trial results presented in American Society of Clinical Oncology June 2023 meeting, the United States Food and Drug Administration approved Talazo + Enza combination as first line therapy in mCRPC on June 20, 2023. In future, with availability of more data, this combination can be adopted as first-line treatment in mCRPC depending on accessibility and affordability to the patients in our country. Financial support and sponsorship: Nil. Conflicts of interest: There are no conflicts of interest.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Prashant Shekhar Gupta (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: